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Abstract 
A prospective study of the thyroids of 289 normal fetuses was 
performed sonographically to establish normal values of fetal thyroid 
volume for the gestational period between 20 and 36 weeks. The lengths of 
the three longest axes of each thyroid lobe were measured for the 
calculation of the volume of separate lobe by the Ellipsoid equation (V = 
Thickness x Width x Length x n/6). The volume of the isthmus was 
estimated as being 5% of the volume of both lobes. The FTV was the sum 
of the volume of both lobes and the isthmus. Another 72 fetal thyroids from 
those mothers with past or active Graves' disease were evaluated and 
compared to the normal values. 
The normal fetal thyroids were found to increase with gestational age 
in an exponential manner. This agreed with the maturation process of the 
fetal thyroid reflected by the fetal total T^ concentrations shown in published 
studies. The mean (±SD) FTV was 0.23 土 0.18 crrf (range: 0.022cnf -
0.85cnf; median 0.17crrf). The rate of growth was fastest during late 
gestation being 0.054cmyweek after 32 weeks as compared to 
0.051crrf/week and 0.055crrf/week in the treated and untreated groups of 
the thyrotoxic population at the corresponding period ofgestation. 
All 72 FTVs in this thyrotoxic population were all within the normal 
range. The trend of FTVs in the treated group was relatively constant 
around the mean independent of the maternal thyroid status while the FTVs 
V 
in the untreated group varied over a wider range within the normal limits. It 
seems that antithyroid treatment regularizes the fetal thyroid growth in 
thyrotoxic mothers, but that immunoglobulins may still affect the fetus and 
neonate in mothers with a past history of thyrotoxicosis. 
. The mean fetal thyroid volume to estimated fetal weight C^A/V) ratio (± 
SD) in the normal fetuses was relatively constant throughout the gestation 
equal to 0.163 土 0.079 cnf/kg which was smaller than those for the child 
and the adult reported in the literature. The difference suggested that fetal 
thyroid enlargement underestimation may occur if postnatal criteria were 
used. The mean value under 36 weeks (0.161 土 0.080 cnf/kg) was 
significantly smaller than that over 36 weeks (0.200 土 0.061 cnf/kg). This 
finding may indicate that the fetal thyroid gland grows more near term in 
preparation for the role of thermogenesis in the postnatal life, in addition to 
stimulating growth and development of the central nervous system 
antenatally. The range of z scores of the VAA/ ratios was significantly 
narrower and the values smaller in the treated than in the untreated group 
implying that this group offetuses was less prone to have fetal goiter. 
Low birth weight infants were more frequent in the thyrotoxic 
population than in the normal population with a percentage of 11.5 in which 
LBW infants were predominantly in the treated group. Although treatment 
may regularize fetal thyroid growth, it does not seem to ensure normal fetal 
growth. Therefore, careful monitoring of fetal thyroid and somatic growth 
throughout the pregnancy by serial fetal ultrasound is crucial. The 
nomogram and normal reference for fetal thyroids in this study should be 
useful to help achieve the best possible outcome. 
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Background 
Graves' disease is the commonest cause of hyperthyroidism in 
pregnancy (Becks & Burrow 1991)，particularly so in the E a s t 、 
including Hong Kong. It is well recognized that adverse effects of the 
disease itself and its medical treatment by antithyroid drugs may lead to 
either fetal hyperthyroidism or hypothyroidism. The affected fetus may 
present with a spectrum of abnormalities in which fetal goiter and/or 
intrauterine growth retardation (IUGR) are common. If fetal thyroid 
dysfunction is undiagnosed in utero, it may significantly increase fetal and 
neonatal morbidity and mortality (Becks & Burrow 1991, Sipe & Malee 1992， 
Polk1994, Seely & Burrow 1994). 
As the infants of thyrotoxic mothers have a higher risk for thyroid 
dysfunction in association with a variety of abnormalities, early in-utero 
diagnosis is mandatory so that maternal therapy could be adjusted. If 
necessary, even fetal therapy could be instituted. 
Unfortunately, there is no satisfactory indicator for fetal thyroid 
function. Abnormal fetal heart rate and IUGR are too poorly correlated with 
fetal thyroid status to be used as indicators for abnormal thyroid function 
OA/allace et al 1995). 
Fetal goiter is specific for fetal thyroid disease, fetal thyroid volume 
may give an indication of possible fetal thyroid disorder. However, the data 
1 
available in the literature for fetal thyroid dimension are limited to those 
established by Bromley et al of fetal thyroid width and fetal thyroid 
circumference (Bromley et al 1992). However, this study included the 
trachea in the measurements. Furthermore, these data could not b e 、 
compared with postnatal thyroid volumes which have been recorded in all 
other age groups. 
The objectives of this study therefore were to establish a nomogram 
for fetal thyroid volume (FTV) related to gestational age, to evaluate the 
relationships of FTV to other growth parameters, to calculate the growth rate 
of normal fetal thyroid glands, to obtain the value of Fetal Thyroid Volume to 
Estimated Fetal Weight O^^W) ratio which is a parameter commonly used in 
the paediatric and adult population, and to compare the FTVs in the normal 
population against those in the thyrotoxic population, with an aim of 





Chapter 1 Introduction 
1.1 Thyrotoxicosis 
I 
Thyrotoxicosis is a syndrome produced by excessive quantities of 
either endogenous or exogenous thyroid hormone, while the term 
'hyperthyroidism' is used to denote only those conditions in which sustained 
hyperfunction of the thyroid leads to thyrotoxicosis (Braunwald et al 1987). 
Thyrotoxicosis is common in pregnancy with reported incidences ranging 
from 0.04% to 1.4% (average 0.2%) (McDougall 1989). The aetiology of 
thyrotoxicosis in pregnancy includes Graves' disease, toxic multinodular 
golter, toxic adenoma, trophoblastic neoplasia, pituitary hypersecretion of 
TSH, metastatic follicular cell carcinoma, De Quervain's thyroiditis, silent 
lymphocytic thyroiditis and struma ovarii 0"able 1). 
Asian women more frequently develop biochemical evidence of 
thyrotoxicosis at the beginning of the second trimester than the Caucasians 
and are at greater risk of clinically apparent gestational thyrotoxicosis (Price 
et al 1996). It is estimated that about 90 to 95 per cent of thyrotoxicosis in 
pregnancy is due to Graves' disease (Braunwald et al 1987; Seely & Burrow 
1994). However, with our local experience, Graves' disease appears to be 
even more frequent than the reported figure as the cause of gestational 
thyrotoxicosis in this population. 
3 
Subclinical hyperthyroidism is defined as serum thyroid hormone 
levels in the reference range with low serum TSH concentrations. The 
causes include subacute thyroiditis, iodine-induced hyperthyroidism, toxic 
thyroid nodule and Graves' disease with Graves' disease being the 
commonest (Charkes 1996). It has been reported that the frequency of 
subclinical hyperthyroidism is higher in Southeast Asians 0/Veigle et al 1996) 
Table 1. Aetiology of Thyrotoxicosis in Pregnancy 
Common Uncommon Rsr6 
™^aves' d ise^ i¥™~^~T5^ i^ l ^^ iH? iodu la rgoHeT^ H y p e r ^ r e t i o n o f T S h P 
Thyroiditis 
Toxic adenoma 




1.2 Graves' Disease 
Graves' disease is a syndrome which usually includes 
hyperthyroidism, a diffusely enlarged thyroid and in some patients 
ophthalmopathy, dermopathy, finger clubbing and acropachy. The eponym 
derives from Robert Graves' description in 1835 of three women with goiter, 
palpitations, forceful heart beat, and tachycardia. Complications of Graves' 
disease include atrial fibrillation, tachyarrhythmias, periodic paralysis which 
is common in Oriental men, protracted vomiting and, if severe, can progress 
to thyroid storm (McDougall 1991). Thrombocytopenia and hepatitis have 
also been reported in a Chinese man with relapse Graves' disease (Szeto et 
al 1997). 
The aetiology of Graves' disease is incompletely understood but it is 
associated with different HLA genes in Caucasians and the Chinese, in 
whom the HLA associations may be stronger in males than females. It has 
been shown that the positive HLA associations in the Hong Kong Chinese 
are different from those in Caucasians whereas the protective haplotype is 
similar to that described in Caucasians (Cavan et al 1994). 
Graves' disease is more frequent in women of reproductive age 
(Braunwald et al 1987). It is an organ-specific autoimmune disorder 
mediated by a group of antibodies that bind to the TSH receptor on thyroid 
follicular cells. This binding effectively stimulates increased thyroid hormone 
biosysthesis and secretion. The action of the circulating immunoglobulins 
5 
on the TSH receptor are mostly stimulatory but can also be inhibitory (Smith 
et al 1988，Sipe & Malee 1992). It is possible that patients with Graves' 
disease may develop hypothyroidism due to Hashimoto's disease or vice 
versa 0"amai et al 1990，Takasu et al 1990). However, there is no single 
immunological abnormality which can explain all of the clinical features 
(McDougall 1991). 
Ideally, hyperthyroid women should be rendered euthyroid before 
considering conception. The incidence of maternal, fetal and neonatal 
morbidity is significantly higher in those patients whose hyperthyroidism is 
not medically controlled. Maternal morbidity includes a higher incidence of 
toxemia, premature delivery, congestive heart failure and thyroid storm. 
Neonatal morbidity includes small-for-date neonates, prematurity, neonatal 
hypothyroidism or hyperthyroidism. Fetal goitre is occasionally reported in 
infants of thyrotoxic mothers (Mestman 1997). 
Pregnancy may have a favourable effect on the course of Graves' 
disease particularly in the second and third trimesters, but there is a 
tendency for relapse postpartum, usually two to three months postpartum 
(Amino et al 1982). The immune tolerance that develops during pregnancy 




1.3 Laboratory Assessment of the Mothers 
Ever since the introduction of immunometric assays (IMAs) for serum 
\ 
thyrotropin in 1980s and subsequent sensitive sTSH assays, they have 
been advocated as an initial test for thyroid dysfunction. The enhanced 
sensitivity of these tests permits earlier detection of minor thyroid 
dysfunction. The sensitive sTSH assays allow discrimination of the very low 
TSH levels encountered in hyperthyroidism from those found in healthy 
euthyroid individuals. It can also facilitate fine tuning of LT4 replacement 
therapy and monitoring of T4 suppression therapy. With the highly sensitive 
chemiluminescent assay which demonstrates an eight- to ten-fold increase 
in sensitivity over a sensitive IMA, not only can hyperthyroidism be 
distinguished from euthyroidism, but also degrees of TSH suppression in 
subclinical hyperthyroidism can be detected (Ross et al 1989)_ The TRH 
stimulation test in favour previously is now effectively redundant as 
hyperthyroidism can be excluded by a sTSH test (Klee & Hay 1987; Bayer 
1991). Therefore, sTSH was preferred to fT4 "n the determination of 
maternal thyroid status in the mothers who are not on antithyroid treatment • 
An elevated serum free T4 and a suppressed TSH are diagnostic of 
hyperthyroidism. It has been suggested that TSH values <0.05^U/ml are 
Indicative of hyperthyroidism in the absence of pituitary disease (Seely & 
Burrow 1994， Burrow 1995). It is important to differentiate Graves' 
hyperthyroidism from other causes of hyperthyroidism because the 
7 
management of Graves' disease and its potential effects in pregnancy on 
the infants are different from other hyperthyroid states. 
The most useful laboratory test to confirm or exclude autoimmune 
disease in terms of speed and cost is measurement of thyroglobulin (ATG) 
and microsomal (thyroid peroxidase)(AMC) autoantibodies. These 
antibodies are positive in about 80% of patients with Graves' disease or 
Hashimoto disease which may exist without circulating antibodies (Kaplan 
1985，Bayer 1991,Weetman 1994). 
By haemagglutination of red cells coated with the antigen of interest, 
between five to ten per cent of normal individuals, especially older women, 
have a weakly positive titer in each test. In patients with thyroid disease, 
many have only elevated AMC antibody titers, some have elevated titers of 
both and a few have only elevated ATG titers (Kaplan 1985). 
Elevated titers in an euthyroid or hypothyroid patient suggest 
Hashimoto's thyroiditis whereas in a hyperthyroid patient Graves' disease is 
the most likely diagnosis. 
Routine antibody testing will be more effective when sensitive 
immunoassays are used instead of haemagglutination procedures, although 
the findings of thyroid antibodies may still not be in concordance with the 
clinical findings in either method. The clinical utility of immunological 
8 
investigations may include prediction of the risk of congenital 
hyperthyroidism in infants of a pregnant mother with Graves' disease; 
confirmation of a transient neonatal hypothyroidism; prediction of relapse of 
hyperthyroidism after medical therapy, and differential diagnosis of eu thy ro id、 
Graves' disease versus orbital tumour (Bayer 1991). Only the first two uses 
are relevant in this study. 
/ 'I ( 
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1.4 Placental Transfer 
If a woman who had been or is suffering from Graves' disease 
becomes pregnant, her fetus will be at risk of thyroid dysfunction because 
there are a number of maternal thyroid and anti-thyroid agents which can 
pass through the placenta and affect fetal thyroid function. 
in a normal pregnancy，the fetus is essentially protected from the 
effect of maternal thyroid physiology because the placenta is impermeable 
to TSH throughout the pregnancy. The effectiveness of placental transfer of 
T4and T3 is controversial. Earlier studies showed that the placenta was only 
minimally permeable to T4 and T3 at the early stages of gestation (Roti et al 
1983，Fung et al 1986，Polk 1994). However, Vulsma et al have shown that 
placental transfer of T4and T 3 d 0 e s occur at term in a significant amount that 
may be essential to achieve normal cerebral development. They measured 
the serum levels of T4Of 40 infants with congenital hypothyroidism (25 with a 
total organification defect and 15 with thyroid agenesis) at birth and showed 
that a developmentally significant but subnormal level of T4 was present in 
those infants. The subnormal T4 level was between 35 to 70 nmol/litre as 
compared to the normal range 80 nmol/litre to 170 nmol/litre O^uIsma et al 
1989). 
‘ A recent study has reported that although placental transport of 
1 
iodothyronines is limited, significant maternal-fetal transfer of T4 occurs, 
accounting for approximately 30% of the average lO^tg/dL serum-T4 
10 
concentration in fetal-cord blood at term. This maternal contribution to the 
fetal-T4 is important for normal fetal maturation，particularly of the central 
nervous system, both at early gestation before the fetal thyroid gland is 
capable of thyroid hormone systhesis and at late gestation when t h y r o i d 、 
hormones act on multiple organs (Fisher DA 1997). 
In thyrotoxic pregnancies, there are both endogenous and exogenous 
influences. The endogenous effect comes from maternally produced 
immunologlobulins and the exogenous influences are related to the 
therapies that may be applied. 
The placental permeability to various agents is listed in Table 2. 
Iodides, t h y r o t r o p i n - r e l e a s i n g hormone (JRH), TSH-receptor antibodies 
Q-SAb): thyroid-stimulating immunoglobulins (TSIg) and thyroid-inhibitory 
immunoglobulins 0"llg), and thionamide drugs eg. propylthiouracil (PTU) and 
carbimazole ( C M g can cross the placenta. In contrast, the placental 
permeability to TSH and thyroid hormones is relatively low (Burrow 1995). 
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Table 2. Placental Transfer ofMaternal Thyroid and Antithyroid Agents 
Placental Transfer 
High Low No 
、 
Normal TRH T3&T4 TSH 
(Endogenous) 
Abnormal TSAb 丁 3 & 丁 4 TSH 
(Endogenous) 0"Slg &Tllg) 
Exogenous Iodides 
Thionamides T3 & 丁 斗 -
TRH 
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1.5 Effects of Maternal Thyroid and Antithyroid Aaents 
on the Fetus 
Under the effects of maternal thyroid agents and antithyroid 
treatment, it is estimated that 2 to 12 % of fetuses or neonates born to 
mothers with Graves' disease will develop either hyperthyroidism or 
hypothyroidism OA/enstrom et al 1990). In Asia, the incidence seems to be 
much lower. No fetal goitre was detected in a six-year review on 28 cases 
of hyperthyroidism complicating pregnancy in Malaysia (Lim et al 1989) and 
in a 12-year review on 114 cases with same clinical history in Thailand 
(Phuapradit et al 1993). 
1.5.1 Thyroid-Stimulating Immunoglobulins (TSIa) 
Graves' disease (autoimmune thyrotoxicosis), the commonest cause 
of hyperthyroidism in pregnancy, is a result of TSIg binding to and 
stimulating the TSH receptor (McDougall 1989). Thyroid-stimulating 
Immunoglobulins cross the placenta easily and may cause fetal and/or 
neonatal thyrotoxicosis which occurs in about 1% of babies born to women 
with a history of Graves' disease or Hashimoto's thyroiditis (Becks & Burrow 
1991，Shulman & Root 1991，Seely & Burrow 1994). Congenital 
hyperthyroidism is usually transient, lasting only three to 12 weeks after birth 
、 and is independent of the mother's current thyroid status. The risk is 
probably greatest in fetuses of mothers who have had previous ablative 
thyroid treatment as the fetus may be exposed to TSIg throughout the 
13 
gestation and may remain unrecognized (Sipe & Malee 1992). Delayed 
onset is not uncommon and may become chronic as congenital Graves' 
disease (Becks & Burrow 1991). 
V 
Fetal thyrotoxicosis is suggested by a heart rate greater than 160 
beats/min, growth retardation, advanced bone age, premature 
craniosynostosis, fetal goiter and frontal bossing (Becks & Burrow 1991， 
Belfar et al 1991). In severe cases, fetal thyrotoxicosis may lead to with 
i n t r a u t e r i n e death with pathologic findings including pulmonary hypertension, 
visceromegaly, generalized adenopathy, decreased subcutaneous fat and 
thyromegaly (Page et al 1988). Fetal loss in untreated cases approaches 
50% (Bruinse et al 1988). 
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1 5 ？ Thy rn iH - i nh i b i t o r y I m m n n n q l n h i j l i n s m i g ) 
Patients with Graves' disease can occasionally develop 
hypothyroidism from switching TSH-receptor stimulating antibodies to TSH-
receptor inhibitory antibodies. Graves' disease and Hashimoto's thyroiditis ‘ 
can present together in a condition referred to as "hashitoxicosis". Transient 
hypothyroidism after spontaneous resolving Graves' disease may present 
despite increasing TSAb activity (Shigemasa et al 1990). Although TSH-
blocking antibodies cross the placenta readily, they play little role in affecting 
the development of congenital hypothyroidism. This has been shown by a 
study of the immunoglobulins from 15 mothers of infants with congenital 
hypothyroidism. Only one out of 15 of these immunoglobulins exhibited 
TSH-inhibitory activity and was able to block TSH-stimulated iodine 
organification in vitro. This immunoglobulin could inhibit TSH action by 30-
50% in utero, but could not block radiolabelled TSH from binding to its 
receptor. The inhibitory action was only on dibutyryl cyclic AMP stimulation 
of iodine organification implying a unique effect on post-receptor processes 
(Ginsbery et al 1986). 
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1.5.3 Thinnamides (an t i thyro id dmas) 
The thionamide drugs are used most commonly for treatment of 
thyrotoxicosis during pregnancy. PTU and CMZ are the two prinicipal 
thionamides that have been used interchangeably f T h o r p e - B e e s t o n & 、 
Nicolaides 1996). Both PTU and CMZ will inhibit thyroid hormone 
biosynthesis by preventing organification of iodide and coupling of 
iodotyrosines to form T,and T3but PTU can inhibit extrathyroidal conversion 
of T4 to T3 and lower T^ levels faster than CMZ (Sipe & Malee 1992). PTU 
has no known side effect of aplasia cutis in the offspring as has occurred 
with MMI, an active metabolite from CMZ (Van Herle et al 1975; Stephan et 
al 1982; Kalb & Grossman 1986; Burrow 1995). All thionamides cross the 
placenta easily and are excreted into the breast milk. But the placental 
transfer of PTU is four times less and the excretion of PTU into breast milk is 
ten times less than that of CMZ (Cooper 1984; Cooper 1987). 
In spite of all these advantages, PTU tends to accumulate in the fetus 
because of low fetal clearance and this may lead to fetal hypothyroidism 
(Polk 1994). It had been reported that fetal T4 levels were lower in mothers 
under thionamides treatment when compared to those in remission who 
were off treatment (Momotani et al 1986). Cheron et al discovered a lower 
T4level in 11 babies who were born to mothers on combined antithyroid-drug 
treatment in which a higher doses of PTU were used (Cheron et al 1981). 
16 
Methimazole has been associated with a reversible scalp defect, 
aplasia cutis, in the fetus (Stephan et al 1982). Placental transfer of 
thionamides during maternal drug therapy may also induce in-utero 
hypothyroidism or exhibit transient neonatal hypothyroidism. The i n c i d e n c e 、 
of transient hypothyroidism in exposed infants varies from 1% (Blackburn & 
Loper 1992，Burrow 1995) and to about 10% in i o d i n e - d e f i c i e n t endemic 
areas (Becks & Burrow 1991). Infants exposed to antithyroid drugs in utero 
may develop a small goiter (Becks & Burrows 1991). A hypothyroid fetus 
may also present with bradycardia, intrauterine growth retardation (Seely & 
Burrow 1994) and is at risk of neurologic deficits (Rovet et al 1987， 
Heyerdahl et al 1991). 
I 
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1 -B.4 Iodides 
Iodides can readily cross the human placenta. Although iodine is 
essential for fetal thyroid hormone synthesis, excessive iodine levels may 
cause iodide-induced fetal hypothyroidism and goiter. Such levels may 
result from maternal ingestion of iodine-containing proprietary medications 
for treatment of respiratory symptoms or administration of iodides for 
treatment of maternal thyrotoxicosis. In contrast to thionamides, iodides 
may produce a relatively greater fetal goiter which is likely to become 
obstructive (Galina et al 1962) because the mechanisms that protect against 
iodine excess (the Wolff-Chaikoff effect) do not develop in the fetus until 
near term (Shulman & Root 1991, Polk DH 1994). 
1.5.5 Thyrotropin Releasing Hormone CTRH) 
Despite the high permeability of TRH to the placenta, the levels of 
endogenous TRH in maternal blood are too low to affect fetal thyroid 
function. However, maternally administered exogenous TRH is effective in 
increasing fetal levels of TSH and thyroid hormones. As the term fetal 
human pituitary is extremely sensitive to the TSH stimulatory effect of 
exogenous TRH, fetal serum TSH concentration will rise and stimulate fetal 
thyroid to release both T3 and T4 (Roti et al 1981). These findings led to the 
later wide investigation of the therapeutic role of exogenous TRH to promote 
lung maturity in preterm fetuses (Morales et al 1989). 
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1.6 Diagnostic and Screening Tests for Fetal Thyroid 
Dysfunction 
Fetuses at risk of thyroid dysfunction are those of mothers who h a v e 、 
either a current or a previous history of Graves' disease. Correct diagnosis 
ofJeta l thyroid dysfunction must be made before fetal treatment can be 
instituted. Invasive tests allow confirmation of fetal thyroid abnormalities as 
well as direct treatment and are preferred to the less exact clinical 
parameters such as fetal heart rate and weight loss for establishing the right 
diagnosis. 
The invasive diagnostic tests suggested in the literature involve 
indirect determination of fetal thyroid status via amniotic fluid sampling or 
direct quantification via cordocentesis. An elevated reverse T3 (rT3) or TSH 
level in the amniotic fluid may indicate fetal hyperthyroidism or 
hypothyroidism respectively (Kourides et al 1984，Yoshida et al 1986). 
Unfortunately, this method has considerable overlap between the euthyroid 
and hyperthyroid or hypothyroid ranges (Klein et al 1980). A study of 
measurements of amniotic fluid concentrations of iodothyronines and TSH 
reported that these parameters in amnotic fluid did not reliably predict fetal 
thyroid status in pregnancies complicated by maternal thyroid disorders or 
anencephaly. The former included two mothers with untreated 
hyperthyroidism, one untreated hypothyroidism, five hyperthyroid mothers 
on PTU and three hypothyroid mothers on LT4 replacement (Hollingsworth & 
19 
Alexander 1983). Cordocentesis is more accurate compared to the 
relatively insensitive amniotic fluid sampling in predicting fetal thyroid status 
(Porreco & Bloch 1990’ Davidson et al 1991; Polk 1994; Van Loon et al 
1995). 、 
； M e a s u r e m e n t of maternal serum TSlg may give a clue to fetal 
hyperthyroidism. Ultrasound evaluation of fetal heart rate, growth rate, bone 
age and the presence of goiter can be an adjunct to the definitive diagnosis 
of fetal dysfunction (Polk 1994) 0"able 3). 
Cord blood assay at delivery is widely employed as a neonatal 
screening method for congenital hypothyroidism (Daussault et al 1975，Lo & 
Lam 1996), but the assessment and treatment of neonates based on cord 
blood at delivery may already be too late to prevent intellectual impairment 
O"horpe-Beeston & Nicolaides 1996). 
Table 3 Ultrasonic Signs of Possible Fetal Thyroid Dysfunction 
Fetal Hyperthyroidism Fetal Hypothyroidism 
1. Goiter 1. Goiter 
2. Fetal heart rate > 160 beats/min 2. Bradycardia 
3. IUGR 3_ IUGR 
4. Advanced bone age 
5. Premature craniosynostosis 
6. Frontal bossing 
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1.7 Fetal Treatment 
1.7.1 Fetal Hyperthyroidism 
Due to the high placental permeability of thionamide drugs, fetal 
hyperthyroidism resulting from maternal immunoglobulins can be treated by 
maternal oral administration of antithyroid drugs (Polk 1994). It is believed 
that most cases of fetal hyperthyroidism will be treated if the mother is also 
receiving antithyroid drugs for Graves' disease. The dose that maintains the 
mother's thyroxine level in the high normal or slightly elevated range for 
pregnancy appears optimal for fetal thyroid function (Momotani et al 1986). 
In euthyroid mothers, thionamide drugs can still be prescribed to treat the 
fetus if fetal thyrotoxicosis has been diagnosed (Bruinse et al 1988). 
Monitoring of the fetal response to therapy by ultrasonic signs such 
as fetal heart rate > 160 beats/min and IUGR is sensitive. Cordocentesis 
has been suggested to be the definitive method for diagnosis and 
assessment of response to treatment in fetal hyperthyroidism 0^a11ace et al 
1995)，however the need for definitive biochemistry must be balanced 
against the risk of the procedure which is less than 1% of perinatal loss in 
experienced hands _ i n e r 1988) but could be higher in those with less 
experience. 
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17.2 Fetal Hypothyroidism 
In utero therapy for suspected fetal hypothyroidism is difficult. Oral 
treatment of the mother with T4 is ineffective because placental transfer of 
the hormone is inadequate for successful treatment of the fetus (Perelman & 
Clemons 1992; Seely & Burrow 1994). Other possible fetal therapies for 
fetal hypothyroidism include intra-amniotic (Lightner et al 1977)，fetal 
intravascular and intramuscular injections C^an Herle et al 1975) of 丁 ‘ . The 
dose of L-T4 required for adequate replacement is higher for intramuscular 
injection. The intraamniotic approach is generally preferred because of the 
simplicity of the procedure and the longer intervals between administration 
O"horpe-Beeston & Nicolaides 1996). 
The appropriate time for initiation of treatment as well as the 
appropriate dose of T4 for treatment of fetal hypothyroidism remain 
speculative. No information is available regarding the pharmacokinetics of 
human fetal absorption of T4 from amniotic fluid. Treatment regimens used 
are thus arbitrary (Perelman & Clemons 1992). Lightner et al successfully 
treated a hypothyroid fetus with weekly intraamniotic injections of 500^g of 
T4 (Lightner et al 1977). Weiner et al treated a similar fetus with a single 
dose of 200^ig of T4 with reduction of fetal thyroid size _ i n e r et al 1980). 
Perelman et al ultilized the dose of 500fxg of T4 every ten days to 
successfully ameliorate the fetal thyroid status (Perelman et al 1990). The 
optimal frequency and dosage of T4 administration are still not established. 
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Indirect prenatal therapy can also be adopted successfully and safely 
by continuous maternal administration of the thyroid analogue 3,5,3'-
triiodothyroacetic acid CTriac) (Nicolini et al 1996). Normalization of fetal 
thyroid function and reduction of fetal goiter may be achieved. 
In fetal therapy, reduction of fetal goiter is a useful sign to suggest 
the effectiveness of the treatment applied. However, the method of fetal 
thyroid measurement is not consistent in the literature. Some measured the 
thyroid gland as if the goiter is a neck mass, others measured diameters or 
may follow Bromley et al (Avni et al 1992; Hatjis 1993; Hadi et al 1995). 
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1.8 Aims and Objectives of the Research 
1.8.1 Aims 
- To evaluate the feasibility of fetal thyroid volume estimations in 
pregnancy at all gestational ages. 
. To provide a normal reference of the fetal thyroid volume (FTV) for 
the evaluation of possible fetal thyroid disorders secondary to maternal 
hyperthyroidism. 
- To demonstrate the effects of maternal Graves，disease on the fetal 
thyroid gland. 
1.8.2 Objectives 
• To establish nomograms for the FTVs 
• To determine the growth rate of normal fetal thyroids at different 
gestational age intervals 
• To calculate the value of normal FTV to estimated fetal weight ratio 
(V/W) and compare with published data of the paediatric and adult 
population 
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• To compare the FTVs, its growth rate and VyW ratio in the normal 
population with those in a thyrotoxic population^ grouped into 
i. treated/ normal maternal thyroid function 
V 
ii. treated/ abnormal maternal thyroid function 
iii. untreated/ normal maternal thyroid function 
^ jv. untreated/ abnormal maternal thyroid function 
f 
1 In this study, thyrotoxic population refers to all pregnant women with current or past history of 
Graves' disease with or without antithyroid drug treatment. 
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Chapter 2 Subjects and Methods 
2.1 Patients，Profile 
V 
2.1.1 Normal Population 
From December 1994 to May 1996，a total of 289 fetal thyroid glands 
were measured between 20 and 36 weeks of gestation in 289 mothers who 
had no known history of previous or current Graves' disease. All of them 
were referred from either the Obstetrics and Gynaecology department at the 
Prince of Wales Hospital or the Maternity and Care Health centres for 
ultrasound dating of gestation. Multiple gestations and any pregnancies 
complicated by maternal diabetes, hypertension, SLE and smoking were 
excluded from the study. Only one measurement from each pregnancy was 
used to establish the nomogram. 
2.1.2 Thyrotoxic Population 
From September 1995 to March 1997，a total of 184 fetal thyroid 
measurements were made between 20 and 36 weeks of gestation in 72 
mothers who had either a current or a past history of Graves' disease. The 
patients were referred mainly from the Thyroid Clinic of the Medical Unit and 
a few from the Obstetrics and Gynaecology department. Fifty-one mothers 
(70.8%), in addition to the thyrotoxic symptoms, had laboratory proven 
autoimmune thyroid disease with TSAb present in their serum prior to or 
during pregnancy and the rest presented clinically without serum TSAb. 
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The thyroid status of the mothers varied. It could be euthyroid, 
hyperthyroid or hypothyroid. They had either received antithyroid drug 
treatment (eg. PTU or CMZ) due to their current thyrotoxic symptoms before 
the ultrasound scan or remained untreated as remission of the disease had 
occurred. In the latter，some were on L-T4 replacement post thyroidectomy 
or post radioactive-li3i thyroid ablation. The detailed breakdown of the tests 
performed on the mothers' sera will be given later in section 3.2. 
All thyrotoxic mothers after attending the first ultrasound examination 
were rescanned monthly until 36 weeks gestation to monitor fetal thyroid 
volume and fetal growth. If the maternal thyroid function was normal during 
all the scan periods, one value from each set of fetal data was selected to 
test the sensitivity of the nomogram established by this study. If the 
maternal thyroid function was abnormal, only the FTV at the time of 
abnormal maternal thyroid function was used. If the abnormal maternal 
thyroid function persisted for several scans, one value from each set of fetal 
data was selected to represent the whole. 
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2.2 Categorization of the Thyrotoxic Population 
The subjects were divided into four groups according to maternal 
therapy and thyroid status during their attendance at the ultrasound 
、 
examinations. 
i. the treated group with normal maternal thyroid function 
ii. ^ the treated group with abnormal maternal thyroid function 
iii_ the untreated group with normal maternal thyroid function 
iv. the untreated group with abnormal maternal thyroid function 
The maternal thyroid status at the time of scan was determined 
retrospectively by retrieving the most recent result (with respect to the date 
of scan) of maternal thyroid function test on the hospital computer network 
system, LRR (Laboratory Result Report) System. Since the majority of the 
thyrotoxic mothers, irrespective of their current thyroid status, attended the 
Thyroid Clinic at a regular four-week interval until term with serum thyroid 
function test of TSH and/or T4 performed on the same day of the clinic, the 
thyroid status would then be known for most scans. There was no more than 
14 days between the date of thyroid function test and the date of scan. 
The normal reference ranges for serum free T4 (fTJ by one-step 
immunoassays and sensitive TSH (sTSH) immunometric assays quoted in 
the Prince of Wales Hospital are 10.2 to 19.6 pmol/l and 0.3 to 4.0 mlU/l 
respectively. A sTSH value less than 0.03mlU/l is indicative of 
• 
hyperthyroidism in the absence of pituitary disease. In pregnancy, these 
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values are debatable. Free thyroxine concentrations may be slightly lower 
compared to the non-pregnant range by the second trimester and may 
decrease further (by about 30% of its values in early pregnancy) by the third 
V 
trimester. However, the changes in free thyroid hormone concentrations 
remain in the normal range O"amamoto et al 1979, Parker JH 1985). A 
concomitant rise in the serum TSH levels has also been reported (Glinoer et 
al 1990). 
I 
In the treated mothers, the fT4 levels were used to indicate the 
maternal thyroid status. If only sTSH had been obtained, the thyroid status 
was assigned as suggested by reference values. 
In the untreated mothers^，sTSH values were preferred to fT< level for 
initial diagnosis. If only 汀 4 was available, the thyroid status was determined 
as suggested by reference values. 
In both groups, the thyroid status for that scan would be assumed in 
accordance with the clinical condition if no recent maternal thyroid function 
was available (Table 4). 
2 The、untreated, mothers refer to those who were not currently treated with antithyroid drugs, 
therefore those who were on L-T4 replacement were also included in this group. 
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Table 4. Determinating Tests for Maternal Thyroid Status 
Thyrotoxic Maternal Tests that may be available 
Population 
Treated T f ^ |sTSH clinical ‘ 
Untreated l T S H ^ “ f in ica l 
^ *Tests with decreasing order ofpreference from right to left 
for determination ofmaternal thyroid status 
2.3 lntraobserver Error 
The FTVs of thirty fetal thyroids were calculated by the 
measurements of the longest axes of the thyroid lobes. Every axis of the 
lobe was measured on the transverse and longitudinal images. The 
procedures were repeated three times on different images. The three sets 
of FTVs obtained from 30 fetal thyroids were then analysed by one-way 
ANOVA with equal sample sizes to determine the intraobserver variance. 
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2.4 Pilot Studv 
A pilot study was conducted on 40 normal fetal thyroids of 40 
I 
singleton pregnancies during December 94 and January 95 to determine 
which dimension of the fetal thyroid gland was the better estimate of the 
fetal thyroid size. The width, thickness, length and volume of both lobes of 
the fetal thyroid were recorded. The mean width, mean thickness, mean 
length by averaging the measurements of the two separate lobes, and the 
total thyroid volume were correlated with gestational age. The dimension 
that had the strongest correlation with gestational age as reflected by the 
corresponding coefficient of determination R2 would then be taken as the 
sole measurement in this study. 
2.5 Equipment 
All the scans were performed using the high resolution 5MHz 
transducers of the following ultrasound equipment: 
ATL HDI-3000 




The electronic calipers of the five machines are calibrated monthly as 




i. Biparietal Diameter (BPD) 
ii. Femur Length (FL) 
、 
iii. Abdominal Circumference (AC) 
iv. The length of the separate thyroid lobes 
V. The width of the separate thyroid lobes 
vi. The thickness of the separate thyroid lobes 
2.7 Growth Charts emploved 
The nomograms used for all the ultrasonic growth parameters: BPD, 
FL and AC were those established by the Hong Kong Tsan Yuk Hospital 
and in common use in Hong Kong (please see charts in appendix I). 
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2.8 lmaaina Technique 
2.8.1 BPD 
The BPD was measured on an axial plane of the fetal head from outer 
to inner skull table. The intracranial landmarks include the falx cerebri 
anteriorly and posteriorly, the cavum septi pe"ucidi anteriorly and thalami in 
the midline, and the choroid plexus in the atrium of each lateral ventricle 
(Figure 1)(Hadlock FP 1994). 
^ ^ ^ ^ | ^ ^ P ^ ^ f ^ | ^ ^ ^ ^ V 
^ ^ ^ ^ ^ ^ - ^ ^ ^ H | 
^ ^ I M I ^ ^ ^ p ^ ^ S ^ ^ I 
W^m 
^ ^ ^ ^ ^ H 
Figure 1. Axial plane offetal head where BPD is measured. The landmarks should include the 
fabt (F), the cavum septi peUucidi (CSP), thalami (T), the third ventricle (V), the cerebral 
peduncle (P) and the choroid plexus (CP) in the atrium ofeach lateral ventricle 
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2.8.2 FL 
The measurement of the FL was made along the femur diaphysis and 
excluded the distal femora! epiphysis (Figure 2) (Hadlock FP 1994). 
^ ^ ^ 9 H ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H 
H i s i ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ B i ^ ^ ^ ^ ^ ^ ^ ^ ^ B i ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H ^ 
H ^ B Q l ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ H f e ^ ^ ^ ^ ^ ^ ^ ^ B i ^ ! ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ B • 
^ ^ ^ ^ ^ ^ H 
^ ^ H ^ ^ ^ m 
^ ^ ^ ^ 
• H ^ i 
^ ^ ^ ^ ^ ^ ^ ^ B P I I ^ ^ ^ ^ ^ ^ I ^ ^ f e 、 ; > : • 
• • ^ ^ ^ ! • ^ J 
Figure 2. The longitudinal section ofthe fetal femur. The femur length is the distance between 
the two diaphyses as shown by the white arrows. 
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2.8.3 ^ 
The measurement of the AC was taken along the outer-to-outer 
margin of the axial plane of the fetal abdomen where the left portal vein 
enters deep in the liver with the stomach bubble appearing on the left upper 
quadrant (Figure 3) {Hadlock FP 1994). 
^ ^ ^ ^ ^ ^ ^ ^ H 
i ^ m i i ^ ^ ^ ^ ^ m 
1 ^ ^ ^ ¾ 
_ _ ‘ , ^ . 、 - ' ' ^ " ^ f c ^ ^ ^ ^ " ^ ^ ^ ^ ^ H 
蒙 ： ; ^ ^ ， ' ^ • ‘ ^ ; : s . ^ ^ ^ 
Figure 3. The axial plane of the fetal abdomen where AC is measured. The arrow denotes the 
left portal vein in the fetal Uver and a round stomach bubble appears on the left. 
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2.8.4 Linear Measurements of thp Thyroid Lobes 
The fetal thyroid gland was first identifed on the axial scan plane at 
the level of mid-neck as a bilobed homogeneous structure with the carotid 
arteries marking its outer margins (Figure 4a). 
^ The maximum width and thickness of the gland were measured on 
the axial plane of a magnified image (Figure 4b). The favourable fetal 
position is when the fetus lies on its side with no neck flexion. Adequate 
liquor surrounding the fetal neck is an advantage. 
The lengths of the separate lobes were obtained on the coronal plane 
of the fetal neck with trachea lying in between (Figure 5a & b). 
The length of each axis was measured twice. The greater one was 
chosen to avoid underestimation as a result of misalignment during the 
scanning. 
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^ ^ ^ ^ ^ ^ m i ^ ^ ^ H H 
^ ^ ^ 1 ^ : ‘ ^ ^ ^ : 绝 “ ' ' - ^ ^ ^ ^ ^ ^ 1 ^ ^ ^ ^ ^ 
^ ^ M 
凄 i m 
% ^ , ^ 3 ^ K ^ ^ ^ ^ ^ ^ ^ ^ ^ ' 德 { : ^ ^ 冷 《 , _ 臉 鍾 _ « « 
Figure 4a. Transverse section offetal neck. The fetal thyroid is bordered on both sides by the 
carotid arteries (A) and jugular veins (V) with the trachea (curved arrow) lying in the midUne. 
The measurements of the width (short white arrows) and thickness (long white arrows) of the 
separate lobes are demonstrated. ^ ^ —^ , ^ 
Right Z \ ^ Left 
^ n ^ 
aV_^^U U „ J a 
b b 
Figure 4b. The transverse section of the central portion of the normal thyroid 
gland where a,b represents the width and thickness of each lobe 
M 
H H ^ * ^ i " * l l ^ K ^ K i H H H 
^ ¾ ¾ 
H I ^ ^ ^ H 
H p ^ : ^ % ^ ^ ^ | ^m^^M3^ 
Figure 5a. Coronal section ofthe fetal neck. The measurement of the lengths of fetal thyroid 
lobes (double black arrowsheads) are shown. 
0 < c = r ^ ^ 1 
, ^ ^ ^ : ^ Z Z H 7 
Figure 5b. The longitudinal section of the thyroid lobes where c represents 
the length of the long axis 
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2.9 Calculations 
2.9.1 Ffital ThvroiH Volume fFTV) 
The R V was estimated by the Ellipsoid Method with which the 
knowledge of the main axes of the thyroid lobes were required (Ueda 1990; 
Chanoine et al 1991). The FTV was calculated from the formula: 
FTV = V _ t ,obe + V , e f t ,obe + V i s _ u s where 
the partial volume of each lobe V = Jt/6 (a x b x c) and 
a，b, c represents the maximum width，thickness and length of each 
lobe. 
the volume of the isthmus Vis_us = 0.05 0/nghtiobe + Viettiobe) 
9 Q 9 F.Qtimatfiri Fetal Weight fEFW) 
The estimated fetal weight was estimated by the equation utilizing the 
three growth parameters BPD, FL, and AC (Hadlock et al 1985): 
EFW = Logio(birth weight) 
= 1.335 - 0.0034(AC.FL) + 0.0316{BPD)-
0.0457(AC) + 0.1623(FL) 
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2.9.3 Fetal Thyroid Growth Rate 
Fetal thyroid growth rate was calculated by the regression equation of 
FTV versus gestational age. It was the difference of FTVs at a particular 
interval of gestation divided by the corresponding period of gestation. 





2.9.4 Fetal Thvroid Volume to Estimated Fetal Weight Ratio(VAA/) 
The ratio was obtained by dividing the FTV of a fetus with its 
concurrent EFW • 
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2.1Q Gestational Age of the Fetus 
2.10.1 Normal Population 
The gestational age of the fetus in the normal population w a s 、 
determined by averaging the sonographic ages of three growth parameters 
(BPD, FL, and AC), irrespective of the menstrual age. Those in whom the 
difference between BPD, FL and AC was more than seven days were 
excluded. 
2.10.2 Thyrotoxic Population 
For the first scan, the gestational age of the fetus in the thyrotoxic 
population was assigned by averaging the sonographic ages of three growth 
parameters similar to the normal population but ignoring the discrepancy of 
sonographic age between individual growth parameters. The rationale being 
that use of the menstrual age to predict the gestational age of the fetus 
cannot be relied upon as menstrual irregularity and anovulation occur 
commonly in mothers with Graves' disease (Goldsmith et al 1952; Thomas & 
Reid 1987). Discrepancy between individual growth parameters was ignored 
because intrauterine growth retardation is a common reported complication 
of the fetuses of thyrotoxic mothers (Becks and Burrow 1991; Seely and 





I For subsequent scans, the gestational age of the fetus was 
determined by adding the respective time interval to the gestational age of 







2.11 Analytical Methods 
2 .11 .1 Bivariate regression was used to evaluate the relationships 
between FTV and the independant variables BPD, FL, AC, gestational age 
and EFW. 
2.11.2 Multiple regression was employed to analyse more than one 
independent variables: GA and EFW simultaneously, in order to determine 
which variable had the strongest relationship with FTV. 
2 .11 .3 Plots of the residuals, as a diagnostic of homoscedasticity and 
normality of data, were checked for every regression line of best fit on the 
scattergrams. Transformation of data was performed if the assumptions of 
normality and homoscedasticity did not hold. Nomogram of FTVs was 
produced by the predicted mean 土 1.96SD obtained by the regression 
equation. The standard deviation from regression(SD) or the standard error 
of the estimate is equal to the square root of the residual mean square. 
(Daly et al 1991 ； Triola 1994). 
2 . 11 .4 The independent t-test was utilized to compare the means of 
VAA/ ratios of two independent samples: normal versus thyrotoxic 
population, normal versus thyrotoxic treated group, and normal versus 
thyrotoxic untreated group. 
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2.11.5 One-way ANOVA with equal sample sizes was used to 
determine the proportion of variance attributable to intraobserver 
differences. 
〜 
2.11.6 One-way ANOVA with unequal sample sizes was used to 
compare the means of V/W ratios in different age subgroups. 
2.11.7 The Z scores (the number of standard deviations that a given 
value is above or below the mean) of VyW ratios in the treated and 
untreated groups of the thyrotoxic population were calculated and compared 
with the F- test (two sample for variance). 
2.11.8 Wilcoxon rank sum (Mann-Whitney U or Kendall's S) test was 
applied to check if there was significant difference of the FTVs in the treated 
and untreated mothers of the thyrotoxic population. 
2.11.9 The null hypothesis was the absence of correlation or 
difference between the variables considered. The probability value taken to 
indicate statistical significance was p = 0.05. Hypothesis was rejected if p 
was < 0.05. All the statistical analyses were performed using computer 
software Microsoft Excel (version 5) and Statistical Package for the Social 
Sciences (SPSS release 6). 
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Chapter 3 Results 
A total of 289 fetal thyroids from the normal population and 72 fetal 
thyroids (184 measurements) from the at-risk (thyrotoxic) population w e r e 、 
measured between 20 and 36 weeks of gestation. The mean age was 27.6 
weeks for the fetuses in the normal population and 28.4 weeks for those in 
the thyrotoxic population. The normal mean FTV and its relationships with 
different growth parameters, rate of normal fetal thyroid growth, and mean 
VyW ratio were established and compared with the thyrotoxic population. 
3.1 lntraobserver Error 
The three sets of FTV measurements of the thirty fetal thyroids were 
compared with one-way ANOVA and found that there was no significant 
difference between the three sets of data. The intraobserver error was 
hence negligible. 
3.2 Pilot Study 
Forty fetal thyroids of the normal population were included in the pilot 
study. It was shown that FTV had the strongest correlation with gestational 
age reflected by the highest R^ (0.742) compared to all the other linear 
thyroid dimensions (Figure 6-9). Among the three linear dimensions, the 
mean transverse diameter (R^ = 0.6861) is the best and the mean 
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Figure 9. Scattergram of the mean length of thyroid lobes versus GA 
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3.3 Maternal Thvmiri Status rThyrotoxic Population) 
Seventy-two mothers were included in our thyrotoxic population and 
had 184 ultrasound scans for FTV. Determination of maternal thyroid status 
、 
by recent maternal thyroid function tests' was undertaken for each scan. 
The number of maternal thyroid function tests available for correlation of 
FTV at each scan in the treated and untreated groups was listed in Table 5. 
Table 5. Thyroid Function Tests in 72 Thyrotoxic Mothers 
Treated Group Untreated Group 
(34 mothers with 91 scans) (38 mothers with 93 scans) 
" " ^ T e s t s D o n e ~ ~ ~ ~ N o . of Scans Tests Done~~" " "_No . of S c a n s ~ " 
fT4 only 57 fT, only 30 
fT ,+ sTSH 33 fT4+sTSH 30 
sTSH only 0 sTSHonly 10 
none 1 none 23 
In the treated group, all the mothers, but one, had fT4 tests in 
proximity to the ultrasound scans. Thirty-three had, in addition an sTSH 
test. 
In the untreated group, on 40 occasions the maternal thyroid status 
was determined by the results of sTSH tests; on 30 occasions by fT4; and 23 
times by the clinical condition alone. 
3 Recent matemal thyroid function test means test is available or has been done within 14 days prior 
to or following that scan. 
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3.4 Fetal Thyroid Volume (FTV) 
3.4.1 Normal Population 
The normal fetal thyroid gland could be confidently identified and 
measured by ultrasound at around 20 weeks of gestation as a tiny 
homogeneous bilobulated glandular structure lying in the mid-neck 
straddling the trachea and bounded by the carotid arteries laterally. The 
success rate of measuring FTV during the period of gestation from 20 to 36 
weeks was over 90% and then fell toward late gestation. It was found that 
the mean {±SD) FTV was 0.23 土 0.18cm3 (range: 0.022cm=' - 0.85cm'; 
median 0.17cm^) between 20 and 36 weeks of gestation. The FTV 
demonstrated a positive correlation with gestational age in an exponential 
fashion. The respective regression equation at different gestational age was 
y = 0.0035e。i399x where y denoted the FTV and x denoted the gestational 
age (Figure 10). 
Although the regression was better represented by the log(FTV) 
(Figure 11)，the scattergram on the linear scale with a curvilinear regression 
line was easier to use in clinical practice. The nomogram for FTV was 
produced using the predicted mean 土 1.96SD from the regression equation 
(Figure 12). 
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In addition to its positive relationship with GA, the log(FTV) was also 
significantly correlated with BPD, FL, AC and EFW with similar R^「able 6). 
By multiple regression analysis, GA and EFW were significantly correlated 
with FTV (R2 = 0.674; p < 0.0001). The corresponding equation was 
expressed by FTV = 0.38 - 0.02(GA) + 0.3(EFW). The partial correlation 
coefficient of EFW was greater than that of GA (0.365 versus -0.156) with a 
p value (2.27 x lO"。）much smaller than 0.05 . 
Table 6. Relationship between the log(FTV) and different 
independent parameters (n = 289) 
Parameters R^ P 
^ 0 J ^ 6.48 X 10-63 
BPD 0.6773 4.25x10-57 
AC 0.6742 1.63x10-6° 
FL 0.6710 1.3x10-56 
EFW 0.6638 2 . 5 6 x 1 0 " o 
52 
3.4.2 At-risk Group 
Seventy-two fetal thyroids were measured from 184 scans in the at-
risk group during the period from September 1995 to March 1997. The 
FTVs related to different group of maternal thyroid status and therapy were 
plotted against the nomogram (Figure 13-19) and their distribution was 
shown in Table 7. 
Table 7. Distribution of Cases between the Groups 
Groups Number of cases 
Treated euthyroid 24 
Treated (hyperthyroid / hypothyroid) 10 
Treated (PTU) 27 
Treated (CMZ) 7 
Untreated euthyroid 25 
Untreated (hyperthyroid / hypothyroid) 8 
Untreated (on L-T4 replacement) 5 
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Treated Group There were altogether thirty-four fetal thyroids (twenty-
four in the euthyroid, five each in the hyperthyroid and hypothyroid mothers) 
studied in the treated group who had currently received antithyroid treatment 
before the ultrasound scan. We found that the FTVs in these two groups ^ 
with normal and abnormal maternal thyroid function were all within normal 
range and showed a constant trend around the mean irrespective of the 
maternal thyroid status (Figure 13 & 14). 
The distribution of FTVs in the mothers on PTU and CMZ was 
compared and did not appear to differ much from each other. Both groups 
showed little variation around the mean (Figure 15 &16) and absence of 
statistical significant difference. 
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Untreated Group In the untreated mothers (25 euthyroid, five 
hyperthyroid and three hypothyroid), the fetal thyroid sizes were more 
scattered and varied over a wider range within the normal limits (Figure 17 
&18). It was shown that the FTVs in the hyperthyroid mothers were more on 
the higher side above the mean. 
Despite of the apparent difference in the distribution of FTVs in the 
treated and untreated groups, there was no significant difference 
demonstrated in the FTVs between the treated and untreated euthyroid 
mothers, and the treated and untreated hyper-/hypothyroid mothers. 
Further, the size of fetal thyroids in the mothers (n=5) who were on L-T4 
replacement was shown in Figure 19. 
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Figure 17. Distribution of FTVs in the untreated euthyroid mothers (n= 25) 
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3.5 Rate of Fetal Thyroid Growth 
3.5.1 Normal Population 
The fetal thyroid gland grew exponentially with advancing gestat ional、 
age y = 0.0035 e°-^ ®^®' (Figure 10). The rate of thyroid growth was fastest 
towards the end of the pregnancy. The weekly increase was approximately 
0.054 cnr|3 after 32 weeks. 
3.5.2 At-risk Group 
The growth rate of the fetal thyroids in the thyrotoxic group was 
similar to that of the normal population. The weekly increase was 0.052 cm^ 
after 32 weeks by the regression equation 0.0046 6。撒_ Subdividing the 
thyrotoxic group into the treated and untreated subgroups demonstated that 
the weekly increase at the corresponding period of gestation was 
respectively 0.051 cm^ and 0.055 cm^ fTabIe 8). 
Table 8. The growth rate (cm^week) ofFTVin the normal 
and thyrotoxic population 
^ Normal Thyrotoxic Thyrotoxic Thyrotoxic 
(total) (treated) (untreated) 
2 0 ^ 0.010 0.011 0.010 0.011 
24-27 0.017 0.018 0.017 0.019 
28-31 0.031 0.030 0.030 0.032 
32-35 0.054 0.052 0.051 0.055 
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3.6 Fetal Thyroid Volume to Estimated Fetal Weight 
N m Ratios 
3.6.1 Normal Population 
V 
The mean VAA/ ratio th SD) in the normal fetuses was relatively 
constant equal to 0.163 土 0.079 cm=^/kg. By one way ANOVA analysis, there 
was no significant difference demonstrated between each age subgroup (p > 
0.05) CTable 9). 
However, the mean value of VyW ratio under 36 weeks (0.161 土 
0.080 cm'/kg) was significantly smaller than that over 36 weeks (0.200 土 
0.061 cm'/kg). 
Table 9. The VyW ratios in the Normal Population 
GA VyW ratios 
0.163土0.079 cm3/kg 
20-23 0 .165±0.100 
24-27 0.161 ±0.086 
28-31 0.154土0.064 
32-35 0.161 土0.059 
> 3 6 0 . 2 0 0 土 0 . 0 6 1 
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3.6.2 At-risk Group 
The overall mean VAA/ ratio (土 SD) was 0.170 ±_ 0.055 cm^kg. This 
is higher than the overall mean for the normal population (but not statistically 
、 
significant). As the at-risk group is heterogeneous, they were divided into 
the treated and untreated groups. 
The treated group had a V/W ratio of 0.159 土 0.039 cm7kg. This is 
smaller than the normal group but again this difference was not statistically 
significant. 
1 
The untreated at-risk group however had a noticeably larger VyW ratio 
of 0.180 土 0.065 cm^/kg. This was larger than the normal population and the 
treated population, but once again the significance of this group against the 
normals did not reach statistically acceptable levels. 
However, the range of z scores of the V/W ratios was narrower and 
the values smaller in the treated (ranged from -0.72 to 1.24) than in the 
untreated group (ranged from -1.11 to 1.93) (Figure 20 & 21). There was 
significant difference between the two groups (p = 0.0016) 
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3.7 Birth Weight of the Infants 
Birth weight was available in fifty-two infants (28 in the treated and 24 
in the untreated group). Six of them had birth weights at or below 2.5 kg 
(Figure 22). The corresponding percentage of low birth weight (LBW) infants 
was 11.5%. Five of the six infants' mothers were on antithyroid treatment 
during pregnancy. There were two babies born prior to 37 weeks, one at 34 
weeks and one at 35 weeks, equivalent to 3.8% of prematurity. All eight 
mothers, apart from Graves' disease, had no known history of anemia, 
diabetes, cardiac, respiratory, liver nor renal disease. 
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Figure 22. The birth weight of 52 infants in this thyrotoxic population plotted 
against the birth weight chart established by the data obtained from the 
number of births (11,258 neonates with gestational age from week 32 to 41 
in year 95 and 96) at the Prince of Wales Hospital where (o) denotes the 
infants of the treated mothers and (x) denotes the infants of the untreated 
mothers.(-) represents the mean birthweight of the infants in the thyrotoxic 
population at a particular gestational age. 
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Chapter 4 Discussion 
4.1 Methodology 
4.1.1 Volume Measurement - method of choice 
In adults, thyroid size measurement is important in the assessment 
and management of thyroid disease. The thyroid size can be determined by 
palpation, scintigraphy and ultrasonography. Thyroid palpation is a risk-free 
and simple procedure for initial clinical assessment, but skilful palpation of 
the thyroid gland takes practice (Kaplan 1985). A previous study on adults 
in this department showed that clinical palpation of small thyroids 
overestimated their volume by an average factor of almost two (Tsao et al 
1988). This suggests that clinical estimation of thyroid volume by palpation 
is likely to be even more inaccurate in neonates and of course cannot be 
applied to the in-utero 'patient'. 
Scintigraphy had long been accepted for estimation of thyroid size 
which was based on the ellipsoid model, the calculated value was used to 
decide the therapeutic dose of radioactive iodine administered to the patient 
(O'Connor et al 1979; Krasznai et al 1985). This method is inapplicable to 
fetuses due to its radiation hazard and technical difficulty. Ultrasonography 
hence remains the sole method of choice. 
Thyroid size can be reflected by the linear measurements of the 
thyroid gland such as the maximum length of each axis or directly by its 
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volume. The pilot study of 40 fetal glands found that volume measurement 
correlated best with gestational age as it carried the highest coefficient of 
determination, R^ The value was 0.742 for volume measurement while the 
V 
R2for the other linear dimensions were below 0.7. 
Although the nomograms of transverse width and circumference of 
the fetal thyroid have been established in 31 fetuses at low risk of prenatal 
thyroid disease and claimed to be an important reference for thyroid size at 
various gestational ages (Bromley et al 1992), the sensitivity of the 
nomograms is questionable. Firstly, the method of measuring the fetal 
thyroid width and circumference included the fetal trachea in both 
measurements. Secondly, the sample of high risk pregnancies selected to 
validate the nomograms did not seem to be randomized. In that study, five 
out of twenty-three fetuses at risk of thyroid disease developed goiter and 
thyroid dysfunction. The incidence was 21.7%. The overall incidence of 
congenital hyperthyroidism or hypothyroidism in high risk populations is 
estimated to be not greater than one percent (Becks & Burrow 1991). The 
high percentage of fetal goiters detected in their small sample population 
was unusual and therefore their validation may not be reliable. 
If a linear measurement has to be taken to reflect the thyroid size, the 
mean transverse diameter requiring two measurements is recommended as 
it is the second strongest parameter (R^= 0.6861) to correlate positively with 
gestational age. Due to the anatomical location of the thyroid, the 
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transverse section will be the measure with the greatest accuracy. The error 
in determining linear measures in the transverse section was estimated to 
be below 5% and the error of the longitudinal measurement of the lobe was 
found to be less than 10% in adults (Szebeni & Beleznay 1992). 
Four ultrasonic methods are available for determination of thyroid 
volume: Ellipsoid Method, Corrected Ellipsoid Method, Numerical Integration 
and 3-D Ultrasound. 
Thyroid volume measurement (V,obe = thickness x width x length x Jt/6) 
by the ellipsoid approximation of separate lobes of the thyroid gland is 
commonly accepted in spite of its well-known inaccuracy (Himanka et al 
1955; Kelly 1954). The systematic error was as high as 20% (Szebeni & 
Beleznay 1992). 
The corrected ellipsoid method, instead of ultilizing the ellipsoid main 
axes, deduces the volume from the cross-sectional areas which take into 
account the real shape of the gland. As the real areas are measured, the 
corrected ellipsoid method gives less than 5% error (Szebeni & Beleznay 
1992). 
In the numerical integration method, the volume of the thyroid lobes is 
approximated by the sum of volumes of slices of finite width. By employing 
computerized semiautomatic digitizing of the outline of the thyroid gland 
66 
upon the transverse scans, the areas of the transverse sections are 
calculated. Volume measurement is then obtained by numerical integration 
performed along the length of the longitudinal section (Rasmussen & Hjorth 
1974). The volume established by this method also gives less than 5% error 
(Szebeni & Beleznay 1992). 
Three-dimensional (3D) ultrasonography had been shown by several 
studies to be accurate in volume measurements of the prostate gland, 
kidneys and abdominal organs in vitro and in vivo for adult size (Gilja et al 
1994; Gilja et al 1995; Elliot et al 1996), but there are no reported data 
concerning this method as applied to the fetal organ volume measurements. 
3D ultrasound offers various imaging modes in which surface rendering 
gives detailed plastic images if there are surrounding layers of different 
echogenicity allowing for the definition of a certain threshold, transparent 
modes provide an imaging of interior structure of an object, and digital 
documentation of whole volumes is said to enable full evaluation without 
loss of information. Although 3D technology provides an increased number 
of technical options, its applications have to be evaluated for their 
diagnostic significance and limitations in obstetrics and gynecology (Steiner 
et al 1994). 
For the numerical integration and the three-dimensional 
ultrasonography methods, specific equipment other than the available 
conventional real-time ultrasound scanners is required to perform volume 
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measurements. The equipment for the former method is outdated while for 
the latter it is not freely available and its clinical application is still under 
investigation. Due to the unavailability of such kind of equipment in our 
V 
department,丨 excluded the last two methods from my study. 
Although thyroid volume calculated by the conventional ellipsoid 
approximation involved about 20% systematic error and the accuracy could 
be improved by the corrected ellipsoid method or numerical integration 
(Rasmussen & Hjorth 1974; Szebeni & Beleznay 1992)，the ellipsoid method 
was still employed for two reasons. Firstly, the corrected ellipsoid method 
utilizing the cross-sectional areas of the three orthogonal planes is 
technically difficult in a small thyroid lobe_ The measurements of the longest 
axes in the ellipsoid method only involved two perpendicular planes and 
were technically easier. Secondly, the numerical integration required a 
manual compound scanner which was not available in our department. 
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4.1.2 Determination of Maternal Thyroid Status in the Thyrotoxic 
Population _ by biochemical tests 
The use of fT4 and sensitive sTSH measurements is recommended to 、 
define the thyroid status of pregnant women {McDougall 1989; Seely & 
Burrow 1994). However, not all of the pregnant women included in our 
thyrotoxic population had both tests done for the determination of thyroid 
status. The maternal thyroid status was defined usually depending on the 
type of thyroid function test that was available. 
In the untreated mothers, the thyroid status was determined by the 
sTSH assays due to its high sensitivity in detecting suppressed TSH level in 
hyperthyroidism. 
In treated mothers, the thyroid status was decided primarily on the 
value of the fT4 rather than the sTSH. Although many studies indicate that 
sTSH measurements distinguish hyperthyroid as well as hypothyroid from 
euthyroid patients by detecting the very low TSH levels encountered in 
hyperthyroidism, it is not entirely specific for hyperthyroidism. A subnormal 
sTSH may be recorded in the mothers under treatment because the reset of 
pituitary TSH secretion can take weeks to reach a new steady state between 
fT^ and TSH when treatment begins. Therefore sTSH is less useful than 
direct thyroid hormone measurements in establishing degrees of hyper- or 
hypothyroidism and correctly reflect the momentary thyroid status (Bayer 
1991). 
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On 24 occasions, FTV could not be correlated with recent maternal 
thyroid function test (ie. within 14 days). This was always because of 
maternal disease remission and lack of clinical symptoms. These mothers 
did not have 4-week follow-up intervals in the clinic. In such cases, normal 




4.2 Findings and Observations 
4.2.1 Technical Considerations 
It has not been mentioned in the literature that the FTV can be 、 
measured in the normal fetus. This study, however, showed that FTV 
could be confidently identified and measured by the high-resolution 
ultrasound between 20 and 36 weeks. The success rate was over 90% but 
fell towards late gestation. The main reasons for failure were persistent fetal 
occipitofrontal position, hyperflexed fetal neck, oligohydramnios and fetal 
thyroid gland obscured by maternal umbilical shadow. As the fetal head 
started to engage after 36 weeks, FTV measurements were not always 
possible because the fetal neck may be obscured by the maternal pubic 
bone or the fetal neck was hyperflexed to hide the thyroid gland. 
4.2.2 FTV in Normal Population 
in a normal developing fetus, the fetal thyroid hormone concentration 
is a reflection of maturation of thyroid function, which is in turn closely 
related to the total number of functioning units, follicles or acini, formed in 
the developing fetal thyroid gland (lngbar 1987). Therefore the greater the 
number of follicles present in the developing thyroid gland, the more mature 
and larger the gland will be. 
• 
It has been shown in a study of 107 thyroids taken at necropsy from 
patients aged from 1 day to 93 years who did not have any history of 
71 
endocrine disease that the total number of acini in the gland did not show 
any great change with age. This finding implies that the volume changes of 
the thyroid gland at later ages of life are a result of changes in the size of the 
individual acini (Brown et al 1986). It is therefore reasonable to assume that 
the size of the normal fetal thyroid is related to the fetal thyroid hormone 
ccmcentrations，a reflection of maturation of thyroid function, which is 
dependent on the number of acini present. 
Maturation of thyroid function can be divided into three phases: 
embryogenesis (Phase I)，hypothalamic maturation (Phase II) and 
maturation of thyroid system function (Phase III). The process requires a 
complex coordinated series of events involving the hypothalamus, the 
pituitary, the thyroid gland and most peripheral tissues，starting in the first 
trimester (Fisher 1983). 
Embryogenesis (Phase I) occurs during the ten to 12 weeks of 
gestation. During this period, the fetal thyroid gland develops 
morphologically, accumulates and concentrates iodine, and begins to 
synthesize iodothyronines. Both fetal sTSH and T4 are detectable at this 
» 
time but remain at relatively low level until about 16-18 weeks (Fisher 1983; 
Blackburn & Loper 1992). 
Hypothalamic maturation (Phase II) starts from four to about 35 
weeks. TRH is detected in the hypothalamus by ten to 12 weeks by 
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radioimmunoassay and in fetal blood in the third trimester (Blackburn & 
Loper 1992). Histologic maturation of the hypothalamic pituitary portal 
system is largely completed by 30 to 35 weeks of gestation (Fisher & Polk 
1994). 
.Maturation of thyroid system function (Phase III) begins at mid-
gestation and continues until term. A sharp rise of sTSH to a peak at 24 to 
28 weeks is initated by a surge of iodine uptake by the fetal thyroid at 20 
weeks' gestation. The increase in sTSH is followed by a progressive 
increase in serum T4 (Fisher 1983; Wigglesworth & Singer 1991; Blackburn 
& Loper 1992). After 30 weeks, the sTSH level gradually falls until term 
indicating that the fetal hypothalamic-pituitary-thyroid axis is fully functional 
(Fisher et al 1977). However, one recent study disagrees with these 
findings and shows that the sensitivity of the fetal pituitary gland to negative 
feedback inhibition by the rising TJevel is limited and is counterbalanced by 
increasing stimulation by TRH from the hypothalamus O"horpe-Beeston et al 
1991). 
This study found that a positive correlation existed between the 
normal FTVs and GA in Phase ill. The progressive increase in fetal thyroid 
size after 20 weeks did reflect the complex process of maturation of the 
、 thyroid system taking place throughout the gestation (Figure 10). In fact, the 
growth trend of FTVs is similar to the increase in fetal serum T4 
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concentrations with gestation as demonstated by Thorpe-Beeston et al in 
1991a. 
It was also found that FTV was significantly and independently 
correlated to other growth parameters such as BPD, FL, AC, and EFW with 
similar strength. Multiple regression analysis showed that only GA and EFW 
were significantly correlated to FTV in which EFW dominated the effect. The 
results were consistent with the role of thyroid hormone in stimulating 
somatic growth, development of the central nervous system, skeletal and 
lung maturation (Hobel 1980; Seely & Burrow 1994). The positive 
correlation of body weight with thyroid volume had been reported by several 
studies on neonate, child and adult (Hegedus et al 1983; Berghout et al 
1987; Ueda 1990; Chalnoine et al 1991). 
Sex difference in the FTV was not compared in this study but it has 
been reported that there was no significant difference in the thyroid size 
between the female and male neonates although the volume appeared 
slightly higher in boys than in gir1s (Chanoine et al 1991). 
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4.2.3 FTV in Population At-risk 
It is well-recognized that the fetal thyroid is likely to be affected by 
the placental transfer of maternal agents in the thyrotoxic population. 
Although all the fetal thyroids included in this study from the thyrotoxic 
population had FTVs fallen within the normal range，there was a noticeable 
difference in the distribution of FTVs in the treated and untreated groups 
with different maternal thyroid status. 
Furthermore, no fetus in the at-risk group developed a thyroid that 
had a FTV outside the normal range. This is in agreement with the 
estimation of only a one percent chance of developing hyperthyroidism or 
hypothyroidism in fetuses of mothers with active or past Graves' disease 
(Blackburn & Loper 1992，Burrow 1995). As there were only 72 fetuses in 
the at-risk group, it is not surprising that not even one goitre was found. 
Conversely, the 21% possibility demonstrated by Bromley et al should have 
resulted in about 15fetuses or neonates with goitres. 
Although there was no significant correlation between fetal and 
maternal thyroid hormone and TSH in the normal population O"horpe_ 
Beeston et al 1991)，a strong correlation between fetal and maternal T4 
levels had been established in Graves' disease (Momotani et al 1986 ) : 
Maternal T4 level is hence a useful index of fetal thyroid status in the 
thyrotoxic population because the fetal thyroid is affected by the same 
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maternal stimulatory and inhibitory factors including the antithyroid 
treatment. 
In the treated group (irrespective of whether the mothers had no rma l、 
or abnormal thyroid function), the variation of FTVs around the mean was 
less than that in the untreated group. It seemed that antithyroid treatment 
had regularized the fetal thyroid growth. 
The relatively consistent growth trend of the fetal thyroids in the 
treated hyperthyroid and hypothyroid mothers was not expected as 
abnormal maternal thyroid function should reflect suboptimal treatment and 
thereby increase the risk of fetal thyroid enlargement. The unexpected 
observation could be due to the fact that abnormal thyroid function in these 
ten mothers was mostly transient, and maybe as a result of temporary mal-
adjustment of the antithyroid drug dosage. 
In the untreated mothers, great variation of FTVs was shown in both 
groups in which normal and abnormal maternal thyroid function were 
present. The FTVs in the hyperthyroid mothers were more on the higher 
side above the mean. In the five hyperthyroid mothers, four had subclinical 
or mild hyperthyroidism suggested by suppressed sTSH values (<0.03mlU/l) 
but normal fTJevel (Kaplan 1985; Bayer 1991). These findings give further 
evidence to support the potential effects of maternal Graves' disease on 
fetal thyroids, especially in cases where the mothers have had surgical or 
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radioactive iodine thyroid ablation. The mothers may not have active 
thyrotoxicosis and may be euthyroid or hypothyroid, but high levels of TSIg 
persist after thyroid ablation. The fetus may be affected by the placental 
transfer of maternal TSIg throughout the pregnancy without the modi fy ing、 
effects of fetal serum levels of maternally administered antithyroid 
medications (Bruinse et al 1988; Sipe & Malee 1992: Burrow 1995). It has 
been shown that maternal Tllg levels correlated with fetal T4 levels in the 
untreated mothers (Momotani et al 1986). The FTVs of the five mothers 
who were on L-T4 replacement did not differ in size from the rest of the fetal 
thyroids as would be expected from the known relative impermeability of the 
placenta to maternal T4 C^ulsma et al 1989) and absence of its effects. 
Extensive studies had been performed to show the effects of 
antithyroid treatment on the fetus. It has been suggested that thionamides 
may induce in utero hypothyroidism by its high placental permeability with an 
incidence of - 1 % (Burrow 1978). The administration of MMI to pregnant 
women has been associated with aplasia cutis congenita in the offspring 
(Kalb & Grossman 1986). However, previous studies have shown that 
untreated hyperthyroidism resulted in a higher rate of congenital anomalies 
than did treatment with antithyroid drugs. The risk of uncontrolled maternal 
thyrotoxicosis is greater than that of high-dose thionamide therapy. In infants 
of women who were hyperthyroid in the first trimester, the incidence of 
congenital anomalies was significantly higher than in infants of mothers who 
were euthyroid in the first trimester. In addition, hyperthyroidism is best 
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treated prior to conception because the outcome for early treatment before 
pregnancy is better than that for treatment administered during pregnancy 
(Davis et al 1989). 
、 
In a study of 643 infants of hyperthyroid mothers who were treated 
with MMI or underwent subtotal thyroidectomy before and/or during 
pregnancy, six were found to have fetal malformations such as malformation 
of the ear-lobe, omphalocele, imperforate anus, anencephaly, harelip, and 
polydactyly. Two out of 243 infants were from the treated mothers and four 
out of 400 infants from untreated mothers. The respective incidence was 
0.8% and 1.0 % for the treated and untreated cases. (Momotani et al 1984;) 
In the days before therapy was available for hyperthyroidism, the 
perinatal mortality was as high as 48% (Ramsay 1991). Therefore the 
beneficial role of antithyroid drugs far outweigh their teratogenic effect. It is 
believed that most cases of fetal thyrotoxicosis are probably adequately 
treated if the mothers are receiving antithyroid treatment (Bruinse et al 
1988). The optimal dose should be the lowest dose that can keep the 
maternal T4 level in the high normal or slightly elevated range for good fetal 
outcome (Momotani et al 1986). 
This study showed that antithyroid treatment appeared to normalize 
the fetal thyroid growth in the treated group by demonstrating less 
fluctuation in size when compared to those in the untreated group. The 
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observations were compatible with the beneficial role of antithyroid drug 
treatment suggested in previous studies. 
、 
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4.2.4 Rate of Fetal Thyroid Growth 
The growth of normal fetal thyroid glands increased exponentially with 
gestational age. The rate of thyroid growth was 5 times faster in late than in 
mid-gestation. The weekly increase was approximately 0.054cm^ after 
32weeks. It is thought that the mechanism for initiating maturation of the 
fetal thyroid axis is an increase of TSH secretion in midgestation (Hobel 
1980). The fetal TSH concentrations rise and plateau between 20 and 30 
weeks followed by a rise of T4 concentrations (Fisher 1983; Becks and 
Burrow 1992). These findings agree with the observations of this study in 
which the fetal thyroid growth accelerated markedly between the 24-27 
week period (0.017cm7week) and the 28-31 week period (0.031cm^/week) 
(see Table 7) (Figure 23). 
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Figure 23. Comparison of the trend of mean FTVs and Fetal Total T4 at 
different gestational ages (curve of fetal total T4 is taken from the graph of 
Thorpe-Beeston et al in 1991) 
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When comparing the growth rate of FTV in the treated and untreated 
mothers of the thyrotoxic population with that of the normal population in the 
same period of gestation, a slight but insignificant difference of fetal thyroid 
growth rate existed between them. The untreated group had the h i g h e s t 、 
growth rate (0.055cm^/week) compared to the treated which had the lowest 
( 0 . 0 5 1 c m 3 /week) with the normal in between. 
It is recommended to use the lowest possible dose to maintain a 
maternal euthyroid or mildly hyperthyroid state, mild compromise of fetal 
thyroid function cannot be totally excluded because the dose for optimal 
maternal thyroid status may be excessive for the fetus. In our centre PTU is 
prescribed more frequently than CMZ for treatment of thyrotoxicosis during 
pregnancy. It has several advantages over CMZ as the drug of choice in 
pregnancy such as inhibition of extrathyroidal conversion of T4 to T3 efficient 
lowering of T4 levels, no known side effect of aplasia cutis, less placental 
transfer and breast milk excretion (Cooper 1984; Cooper 1987). However, 
this study seems to suggest that there is little difference between PTU and 
CMZ on the FTVs as these are evenly distributed and close to the mean. 
Larger numbers would be required for a more confident conclusion. 
It is well known that the severity of Graves' disease is ameliorated 
during pregnancy, particularly in the second and third trimesters (Becks & 
Burrow 1991; Seely & Burrow 1994). PTU effects must be monitored 
carefully, particularly during the third trimester when remission can lead to 
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decreased thyroid hormone production and decreased requirements for PTU 
(Blackburn & Loper 1992). In the treated group of this study, there were ten 
mothers who had been found to have transient hypothyroidism or 
、 
hyperthyroidism, probably as a consequence of the varying severity of the 
disease and resulting under or over treatment. 
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4.2.5 Fetal Thvroid Volume to Ef^timated Fetal WeightP^AAA Ratio 
For fetal thyroid disorders such as hyperthyroidism and 
hypothyroidism, IUGR and goitre are the two common presentations in 
、 
these conditions (Becks & Burrows 1991). The status of a fetus in the at-risk 
population can be reflected by the V W ratio. The value will be elevated in 
case of an affected fetus suffering from low body weight and/or thyroid 
enlargement. 
The values of mean VyW ratio for normal fetuses under 36 weeks 
(0.161 crr|3/kg) were smaller than those over 36 weeks (this study), and 
those for the child (0.2cm7kg) (Ueda 1990) and the adult (0.274 cm^kg) 
(Hegedus et al 1983) reported in other studies. The difference in mean • 
ratios may imply that fetal thyroid ealargement is less likely to be evident 
and underestimation of fetal goiter may occur if postnatal criteria are used. 
The relatively larger VyW ratio in late pregnancy may reflect a preparation for 
thermogenesis that will be necessary postnatally. 
By simple mathematical deduction, the V/W ratio is directly 
proportional to FTV and inversely proportional to EFW. It means that the 
greater is the value of EFW and/or the smaller is the FTV, the lower the V/W 
ratio will be. The mean V/W ratio depends on the relative percentage 
difference of the thyroid gland and body weight. 
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In fetuses, the variation of body weight was wide within a short 
period of time. The weight of a fetus at 36 weeks of gestation was on the 
average about 8.6 times of the value at 20 weeks in our population (0.35 kg 
、 
at 20 weeks; 3.0 kg at 36 weeks). The increase in FTV (0.057cm' at 20 
weeks; 0.539cm^ at 36weeks) during the same period of pregnancy was 
noticeably greater with a factor of 9.5. This disparity is reflected in the 
change of V/W ratio from about 0.161 cm^/week before 35 weeks and 0.200 
cm3/week after. 
In comparison, weight in normal adults is relatively static and the 
variation of body w e i g h t is much narrower. A study of measuring VyW ratios 
on a group of 111 normal adults in Copenhagen found that the body weight 
of the heaviest subject (100kg) was just 2.5 times of that of the lightest 
(40kg) whereas the proportional difference between the largest (33ml) and 
the smallest thyroid volume (8ml) was about 4.25 times (Hegedus et al 
1983). The relative percentage difference of body weight and thyroid volume 
then ended up with a higher ratio in adults and lower ratio in fetuses with 
intermediate value in children. 
From the V/W ratios, the fetus has the smallest thyroid gland 
compared to the adult and child per unit body weight. This could be related 
to the different roles of thyroid gland in fetal and postnatal life. In utero, the 
function of thyroid gland is mainly to produce adequate thyroid hormones to 
stimulate fetal growth and promote development of the central nervous 
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system. Thermogenesis is less critical for fetus as the mother's womb is a 
thermally stable environment. 
In postnatal life, the role of thyroid gland will switch to establish 
autonomous thermogenesis, apart from stimulating growth and development 
of the central nervous system. The switch is reflected by an acute surge in 
TSH within the first 30 minutes of postnatal life. This surge induces a sharp 
increase in total and free T4 which play a major role of maintaining the body 
temperature when the fetus emerges in the cold extrauterine world (Burrow 
1995). 
The thyroid gland will continue these functions in the later human life 
with the gland slowly growing into the adult size. It has been shown by 
histometric methods that thyroid volume increases with age during childhood 
and adolescence, remains fairly constant in younger adults and declines 
more slowly in older people (Brown et al 1986). 
Besides, a study on 50 healthy subjects in a non-iodine deficient area 
reported much smaller adult V/W values (male: 0.159cm'/kg; female: 
0.132cm3/kg) (Berghout et al 1986). These values were even smaller than 
values for children established by Ueda in a group of normal Japanese 
children and for fetuses in this study. The mean adult thyroid volume (10.7 
cm3) was also smaller compared to that (18.6 cm') of Hegedus et al with 
comparable body weight in the two populations. The lower VyW value 
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demonstrated by Berghout et al should be explained by the smaller mean 
thyroid volume in their population. 
It has been suggested that difference in daily iodine intake, genet ic、 
background and environmental factors could contribute to this difference in 
mean thyroid volume in different geographical areas {McCarrison 1980). 
Aetiologies of goiter vary but may include iodine deficiency, excessive iodine 
intake, or other thyroid diseases (Seely and Burrow 1994). 
In Japan, a study was conducted in five coastal regions including 
Hokkaido to evaluate the prevalence of thyroid dysfunction in relation to 
iodine intake. It was found that hypothyroidism in these areas was more 
prevalent in thyroid autoantibody-negative subjects with high urinary iodide. 
The result indicated that the prevalence of hypothyroidism was related to the 
amount of iodine ingested and marked in excessive iodine intake. In these 
areas, hypothyroidism may be caused by excessive intake of iodine in 
addition to chronic thyroiditis (Konno et al 1994). In the study of Ueda, 
those normal children were living in Hokkaido where iodine-rich seaweed is 
produced. Since the sampled children were from an iodine sufficient area 
where diet-induced hypothyroidism was common, it was reasonable to 
assume that their thyroid volume would be on a higher side to cause a larger 
VyW ratio than that of the adults from a non-iodine deficient area. 
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The study of Hegedus et al was performed in Copenhagen, an area 
of borderline iodine intake. The urinary output of iodine in Copenhagen area 
was BO\xg in 24 hours (Hegedus et al 1983) while an excretion rate of iodine 
greater than 100fxg/24hr has been quoted to be the result of an adequate 
iodine intake (Seely and Burrows 1994). Therefore mild compensatory 
hypertrophy of the thyroid may be common in Copenhagen. 
The same principle may apply to fetuses in Hong Kong. In a recent 
study done by Kung et al on urine iodine excretion of a group of healthy 
volunteers (104 children, 112 adults and 349 elderly) in 1996，it was found 
that 45.3% of the children, 51.7% of the adults and 55.3% of the elderly had 
urine iodine concentration below the cutoff for iodine sufficiency (0.79 
mumol/l). A dietary survey in the same study revealed that seafood was not 
commonly consumed in our population. Fifty to eighty percent of the 
subjects never consumed high-iodine containing food such as seaweed, 
kelp or laver and only fifty percent consumed seawater fish daily (Kung et al 
1996). Although Hong Kong is a coastal area where seafood supply is rich, 
iodine insufficiency does exist. 
In fact, high incidence (23%) of transient neonatal hypothyroidism 
and a relatively high mean cord blood TSH concentration are reported in our 
population (Kung et al 1997). In the study of Kung et al in 1997，35.8% of 
the pregnant women had urinary iodine excretion below the cutoff of 
0.79mumol/l. The borderline iodine supply affected the maternal and fetal 
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thyroid function as demonstrated by a negative correlation between 
maternal TSH and urinary iodine concentration as well as higher cord blood 
TSH in those infants whose mothers had a low urinary iodine concentration 
as compared to those in infants with normal maternal urinary i o d i n e 、 
excretion. 
As maternal ingested iodine readily reaches the fetus and stimulate 
the fetal thyroid, persistent deficient iodine supply to the fetus may induce 
larger fetal thyroid size as a result of compensatory hypertrophy. It is then 
expected to account for the high fetal • ratio when compared with the 
adult value of Berghout et al. 
Furthermore, thyroid disease with goiter is common in our population. 
In a recent study of 240,000 Hong Kong Chinese children under the age of 
15 from 1990 to 1994， there were forty-six Chinese children who had 
confirmed diagnosis of Graves' disease. The overall incidence was 
3.8/100,000/year which was about five times that reported in Danish 
children OA/ong et al 1995). The exact reasons for the high incidence rate in 
Chinese children in Hong Kong are unknown but larger thyroid size may be 
expected in the Hong Kong normal population either due to relative iodine 
deficiency or dinical and subclinical Graves' disease. 
Absence of siginificant difference was demonstrated between the 
V/W ratios of the normal population and the thyrotoxic population including 
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the subgroups. However, there was a slightly higher value (0.18) noted in 
the untreated group implying that there was an insignificant number of 
fetuses in the untreated group who had marginally low EFW and/or 
marginally high FTVs. 
It was found that significant difference was existed between the range 
of z scores in the treated and the untreated groups with the range narrower 
and the values lower in the treated than in the untreated group meaning that 
the VyW ratios in the treated group were relatively constant. As an elevated 
V/W value may reflect either fetal thyroid enlargement or IUGR or both, the 
lower Z values obtained in the treated group would indicate this group of 
fetuses was less likely to have fetal goiter and/or IUGR. This observation 
further supports the benefit of antithyroid treatment in the active thyrotoxic 
mothers. 
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4.2.6 Intrauterine Growth 
Even with treatment, there are slightly more stillbirths and neonatal 
deaths in the thyrotoxic population than in the normal population and the 
V 
mean birth weight was found to be lower than those born to normal women 
(the mean birth weight of white babies was 363g lower and of black babies 
184g lower than those born to normal women) (Ramsay ID 1991). A study 
of two hundred and thirty pregnant women with Graves' disease also 
demonstrated a slight increase in the neonatal mortality rate and a 
significant increase in the frequency (6.5%) of delivery of LBW infants 
(Mitsuda et al 1992). This study is in agreement with the reports above. An 
11.5 per cent frequency of LBW infants was encountered with birth weight at 
or below 2.5kg at term. During the period 95 to 96，the incidence of LBW 
infants overall was 3.64% (500 in 13,727 infants). 
Small babies were more common in this thyrotoxic population than in 
our normal population. The incidence of LBW infants in Hong Kong Chinese 
is low. in a previous study this was 2.9% as compared to 4.3% in Hong 
Kong British (Lyon AJ 1987). Although LBW neonates tend to be less 
common in Chinese pregnancies than in Caucasian pregnancies, it seems 
that this is not the case for thyrotoxic pregnancies. In fact this makes the 
11.5% incidence even more striking. 
Further, antithyroid drug treatment did regularize fetal thyroid growth, 
but five of six LBW infants were from mothers who were on antithyroid drug 
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treatment. Therefore, the regularization of fetal thyroid growth is not by itself 
sufficient to indicate normal progress of pregnancy. Careful monitoring of 
fetal growth and fetal well-being is important in thyrotoxic pregnancies. 
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Chapter 5 Conclusions 
Maternal autoimmune thyroid disease, most commonly Graves' 
disease, is well-known to pose adverse effects on the fetus by the c irculat ing、 
stimulatory and inhibitory autoantibodies or by the medical treatment itself. 
The affected fetus may develop thyroid dysfunction, growth retardation, fetal 
abnormalities or in severe case, fetal death. It is therefore essential to 
diagnose early thyroid disorder in the fetus and apply treatment accordingly. 
Diagnosis and therapy nowadays can be made by cordocentesis. This is 
the most accurate but is an invasive procedure. Fetal thyroid ultrasound 
can be a non-invasive diagnostic test, diagnosing and screening the 
presence of fetal goiter and monitoring the size after treatment • 
In this study, a nomogram for FTV and some related parameters such 
as FTV growth rate and VyW ratio have been established to serve the 
purposes stated above. Fetal thyroid size is better reflected by the FTV 
compared with any other single dimension of the gland. Measurement of 
FTV is feasible between 20 and 36 weeks of gestation. 
From the observations of this study, a better picture was obtained on 
how the fetal thyroid of a thyrotoxic mother is affected by the maternal 
thyroid disease with and without treatment. Treatment appears to regulate 
fetal thyroid growth by showing a more constant growth trend near the 
mean. Transient variations of the dose of antithyroid drugs with resulting 
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abnormal maternal thyroid function does not seem to affect the fetal thyroid 
gland. 
The fetuses of mothers with Graves' disease, either active o r 、 
previously active prior to the pregnancy but not taking any antithyroid 
treatment, have FTVs more variable in size. In fact, subclinical 
hyperthyroidism is common in the mothers who have remission of disease 
post-surgical or radioactive thyroid ablation. Therefore this group of fetuses 
still warrants attention as the maternal immunoglobulins may still affect the 
fetus and subsequently the neonate. 
In addition, diminished growth is more common in the thyrotoxic than 
the normal population. 
Based on the known risks of maternal Graves' disease, serial fetal 
thyroid ultrasound is recommended in addition to the routine antenatal scan 
for every at-risk fetus for monitoring thyroid growth and somatic growth. The 
nomogram and normal reference for fetal thyroids in this study should be 
applied to help achieve the best possible outcome. 
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